AlvotechALVO
ALVO
About: Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
Employees: 999
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 31 [Q2] → 32 (+1) [Q3]
2% more capital invested
Capital invested by funds: $180M [Q2] → $184M (+$3.58M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
0.19% less ownership
Funds ownership: 5.37% [Q2] → 5.19% (-0.19%) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for ALVO.
Financial journalist opinion
Based on 3 articles about ALVO published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025. "This is a significant step towards being able to offer U.S. patients access to biosimilar golimumab," said Joseph McClellan, Chief Scientific Officer of Alvotech. “Our in-house capability allowing us to match the cell line and process used to manufacture the reference biologic, has given us an important head start in developing a biosimilar candidate to Simponi® and Simponi Aria® for global markets." Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva, added, “Biosimilars are ushering a new treatment paradigm and have become an integral staple in the healthcare ecosystem. Teva's strategic partnership with Alvotech underscores our commitment to continue to bring cost-saving options to more patients and deliver better outcomes for those with inflammatory conditions.”
Neutral
GlobeNewsWire
1 week ago
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025.
Positive
Zacks Investment Research
2 weeks ago
Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year?
Here is how Alvotech (ALVO) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
Negative
Zacks Investment Research
1 month ago
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Here is how Alvotech (ALVO) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
1 month ago
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
REYKJAVIK, Iceland, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech's inclusion in the NBI will be effective when the U.S. market opens on Monday, December 23, 2024.
Neutral
GlobeNewsWire
1 month ago
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech's inclusion in the NBI will be effective when the U.S. market opens on Monday, December 23, 2024.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade
The mean of analysts' price targets for Alvotech (ALVO) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?
Here is how Alvotech (ALVO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Negative
Seeking Alpha
2 months ago
Alvotech's Position In The Coming Biosimilar Gold Rush
Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector.
Neutral
Seeking Alpha
2 months ago
Alvotech (ALVO) Q3 2024 Earnings Call Transcript
Alvotech (NASDAQ:ALVO ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director, Investor Relations and Global Communications Robert Wessman - Chairman and Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategy Officer Conference Call Participants Balaji Prasad - Barclays Niall Alexander - Deutsche Bank Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alvotech's Third Quarter 2024 Earnings Conference Call.
Charts implemented using Lightweight Charts™